BR112022004630A2 - Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5) - Google Patents

Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)

Info

Publication number
BR112022004630A2
BR112022004630A2 BR112022004630A BR112022004630A BR112022004630A2 BR 112022004630 A2 BR112022004630 A2 BR 112022004630A2 BR 112022004630 A BR112022004630 A BR 112022004630A BR 112022004630 A BR112022004630 A BR 112022004630A BR 112022004630 A2 BR112022004630 A2 BR 112022004630A2
Authority
BR
Brazil
Prior art keywords
prmt5
inhibitors
protein arginine
arginine methyltransferase
selective protein
Prior art date
Application number
BR112022004630A
Other languages
English (en)
Portuguese (pt)
Inventor
Ganfeng Cao
Hongwu Yu
Huaping Zhang
Qun Li
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of BR112022004630A2 publication Critical patent/BR112022004630A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
BR112022004630A 2019-09-18 2020-09-18 Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5) BR112022004630A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962902322P 2019-09-18 2019-09-18
PCT/US2020/051563 WO2021055797A1 (en) 2019-09-18 2020-09-18 Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Publications (1)

Publication Number Publication Date
BR112022004630A2 true BR112022004630A2 (pt) 2022-05-31

Family

ID=72717922

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004630A BR112022004630A2 (pt) 2019-09-18 2020-09-18 Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)

Country Status (12)

Country Link
US (2) US12414953B2 (https=)
EP (1) EP4031555A1 (https=)
JP (1) JP7706166B2 (https=)
KR (1) KR20220065811A (https=)
CN (1) CN114829370B (https=)
AU (1) AU2020349553A1 (https=)
BR (1) BR112022004630A2 (https=)
CA (1) CA3154566A1 (https=)
IL (1) IL291417B2 (https=)
MX (1) MX2022003340A (https=)
WO (1) WO2021055797A1 (https=)
ZA (1) ZA202203680B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116211869B (zh) * 2022-12-07 2023-08-01 浙江省肿瘤医院 含dna损伤修复抑制剂的药物混合物及混合方法、用途
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US20170198006A1 (en) * 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016022605A1 (en) * 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
MX2017010844A (es) 2015-02-24 2017-12-07 Pfizer Derivados de nucleosidos sustituidos utiles como agentes anticancerosos.
MA41827A (fr) * 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
AU2017230658B2 (en) 2016-03-10 2021-03-04 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
CN108430987B (zh) * 2016-06-02 2021-06-18 上海海雁医药科技有限公司 Pi3k抑制剂及其药学上可接受的盐和多晶型物及其应用
WO2017218802A1 (en) * 2016-06-15 2017-12-21 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
TN2019000087A1 (en) * 2016-10-03 2020-07-15 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
KR101785870B1 (ko) 2016-11-03 2017-10-13 한규락 오르골 장치
EP3939986A1 (en) 2017-08-09 2022-01-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2019084470A1 (en) 2017-10-26 2019-05-02 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
AU2019235912B2 (en) 2018-03-14 2024-03-21 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

Also Published As

Publication number Publication date
JP7706166B2 (ja) 2025-07-11
IL291417B2 (en) 2025-12-01
US12414953B2 (en) 2025-09-16
CN114829370B (zh) 2025-10-28
WO2021055797A9 (en) 2021-04-22
AU2020349553A1 (en) 2022-04-07
IL291417B1 (en) 2025-08-01
WO2021055797A1 (en) 2021-03-25
JP2022548689A (ja) 2022-11-21
US20230029094A1 (en) 2023-01-26
CA3154566A1 (en) 2021-03-25
MX2022003340A (es) 2022-06-14
IL291417A (en) 2022-05-01
CN114829370A (zh) 2022-07-29
KR20220065811A (ko) 2022-05-20
EP4031555A1 (en) 2022-07-27
US20250367205A1 (en) 2025-12-04
ZA202203680B (en) 2025-12-17

Similar Documents

Publication Publication Date Title
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
BR112022004248A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer
MX374497B (es) Inhibidor del antígeno de superficie del virus de la hepatitis b.
BR112017017135A2 (pt) inibidores de tgf-beta
BR112021018950A2 (pt) Compostos de imidazolonilquinolina e seus usos terapêuticos
BR112021022536A2 (pt) Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo
MX382991B (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
BR112012024199A2 (pt) derivados de n-(imidazopirimidin-7-il)-heteroarilamida e seu uso como inibidores de pde10a
EA201391239A1 (ru) Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
BR112022004327A2 (pt) Inibidores de cdk e seu uso como fármacos
SA521421645B1 (ar) بيرولينات إندماجية تعمل كمثبطات بروتياز نوعي لأوبيكويتين 30
ZA202105887B (en) Selective inhibitor of protein arginine methyltransferase 5 (prmt5)
CU20100238A7 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
NI200900134A (es) Derivados de imidazol como inhibidores de proteína de huso de cinesina (eg-5).
MX2019002915A (es) Derivado de ?-aminoacido triciclico fusionado, metodo de preparacion, y su uso medico del mismo.
ZA202005325B (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
MX2023007265A (es) Inhibidores de cdk y su uso como productos farmacéuticos.
MX2020003993A (es) Derivados de bencimidazol y sus usos.
EA202192845A1 (ru) Новые композиции, содержащие мелфлуфен
BR112015024109A2 (pt) derivados de ureia e seu uso como inibidores de proteína de ligação de ácidos graxos (fabp)
BR112022004630A2 (pt) Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: PRELUDE THERAPEUTICS INCORPORATED (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]